Phase I Study of Chemotherapy and Proton Therapy for Pancreatic Cancer
This study is testing the highest safe dose of two chemotherapy drugs, nab-paclitaxel and gemcitabine, when given with proton therapy for locally advanced pancreatic cancer (LAPC). LAPC is cancer that has not spread to other parts of the body but cannot be removed by surgery. You would receive proton therapy once a day, Monday through Friday, for three weeks. You would also receive chemotherapy on each Monday during those three weeks. The study aims to find the maximum tolerated dose of these treatments. To join, you must be between 18 and 75 years old and have pancreatic adenocarcinoma that has not spread. The study plans to enroll 24 participants, but its current status is unclear.
- Study design
- This is a Phase I study designed to find the maximum tolerated dose of the treatments. It plans to enroll 24 participants.
- What's involved
- You would receive proton therapy once a day (Monday - Friday) for 3 weeks. You would also receive chemotherapy on each Monday of those three weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 12 months after registration or until death, whichever occurs first.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase I Nab-Paclitaxel Plus Gemcitabine With Proton Therapy for Locally Advanced Pancreatic Cancer (LAPC)
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Jason Molitoris, MD · PRINCIPAL_INVESTIGATOR · University of Maryland/Maryland Proton Treatment Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Maximum Tolerated Dose of Gemcitabine and nab-Paclitaxel in LAPC patients receiving proton therapyPatients will be followed for 12 months after registration or until death, whichever occurs first.
Maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of concurrent nab-paclitaxel + gemcitabine combined with hypofractionated ablative proton therapy for the treatment of locally advanced pancreatic cancer.